Abstract
Introduction Increasing corona virus disease 2019 (COVID-19) pre-test probability can minimize testing patients who are less likely to have COVID-19 and therefore reducing personal protective equipment and COVID-19 testing kit use. The aim of this study was to identify patients who were likely to test positive for COVID-19 among symptomatic patients suspected of having COVID-19 during hospitalization by comparing COVID-19 positive and negative patients.
Method We conducted a retrospective chart review of patients who were ≥18 years old and underwent COVID-19 Polymerase chain reaction test because they presented with symptoms thought to be due to COVID-19. The Poisson regression analysis was conducted after clinical presentation, demographic, medical co-morbidities, laboratory and chest image data was retrieved from the medical records.
Results Charts of 277 and 35 COVID-19 negative and positive patients respectively were analyzed. Dyspnea (61%) was the most common symptom among COVID-19 negative patients, while 83% and 77% COVID-19 positive patients had cough and fever respectively.
COVID-19 positive patients were more likely to present initially with cough [1.082 (1.022 - 1.145)] and fever [1.066 (1.013 - 1.122)], besides being males [1.066 (1.013 - 1.123)] and 50 to 69 years old [1.090 (1.019 - 1.166)]. Dyspnea, weakness, lymphopenia and bilateral chest image abnormality were not associated with COVID-19 positivity.
COVID-19 positive patients were less likely to have non-COVID-19 respiratory viral illness [0.934 (0.893 - 0.976)], human immunodeficiency virus [0.847 (0.763 - 0.942)] and heart failure history [0.945 (0.908 - 0.984)]. Other chronic medical problems (hypertension, diabetes mellitus, chronic obstructive pulmonary disease and coronary artery disease) were not associated with testing positive for COVID-19.
Conclusion Cough and fever are better predictors of symptomatic COVID-19 positivity during hospitalization. Despite published studies reporting a high prevalence of lymphopenia among COVID-19 positive patients, lymphopenia is not associated with the risk of testing positive for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Unfunded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PeaceHealth institutional review board (IRB) approved the study and waived the written informed consent requirement. IRB #1591426-3
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data referred to in the manuscript is available in the manuscript.
